# Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

> **NCT06978062** · PHASE1 · NOT_YET_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 27 (estimated)

## Conditions studied

- GastroEsophageal Cancer

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** FLOT

## Key facts

- **NCT ID:** NCT06978062
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2028-09-11
- **Final completion:** 2029-09-28
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978062, "Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06978062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*